{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:45:16Z","timestamp":1762094716535,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI150461","AI150466"],"award-info":[{"award-number":["AI150461","AI150466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006151","name":"Basic Energy Sciences","doi-asserted-by":"publisher","award":["W-31-109-Eng-38"],"award-info":[{"award-number":["W-31-109-Eng-38"]}],"id":[{"id":"10.13039\/100006151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bbrc.2021.05.094","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:48:04Z","timestamp":1623070084000},"page":"30-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17"],"prefix":"10.1016","volume":"566","author":[{"given":"Johnson","family":"Agniswamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Kneller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-1841","authenticated-orcid":false,"given":"Arun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-7393","authenticated-orcid":false,"given":"Irene T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.05.094_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1086\/515591","article-title":"Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315","volume":"178","author":"Lederman","year":"1998","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.bbrc.2021.05.094_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/505147","article-title":"The survival benefits of AIDS treatment in the United States","volume":"194","author":"Walensky","year":"2006","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.bbrc.2021.05.094_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.bbrc.2021.05.094_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bbrc.2021.05.094_bib5","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.bbrc.2021.05.094_bib6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"A.C.T.G.S.A. Team, Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2021.05.094_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.bbrc.2021.05.094_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmb.2004.02.052","article-title":"High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains","volume":"338","author":"Tie","year":"2004","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bbrc.2021.05.094_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bbrc.2021.05.094_bib10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/jm049560p","article-title":"Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor","volume":"48","author":"Surleraux","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2021.05.094_bib11","doi-asserted-by":"crossref","first-page":"13845","DOI":"10.1128\/JVI.01184-07","article-title":"Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier","volume":"81","author":"Dierynck","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2021.05.094_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/aid.2007.0173","article-title":"Resistance profile of darunavir: combined 24-week results from the POWER trials","volume":"24","author":"de Meyer","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.bbrc.2021.05.094_bib13","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1073\/pnas.1102278108","article-title":"Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors","volume":"108","author":"Louis","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.05.094_bib14","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1021\/ct300032r","article-title":"How does darunavir prevent HIV-1 protease dimerization?","volume":"8","author":"Huang","year":"2012","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.bbrc.2021.05.094_bib15","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1093\/jac\/dkw343","article-title":"U.H.D.R. Database, U.K.C.H.I.V.C.S.S.C. and the, U.H.D.R. Database, U.K.C.H.I.V.C.S.S.C. the, HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK","volume":"71","author":"El Bouzidi","year":"2016","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.bbrc.2021.05.094_bib16","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/infdis\/jix137","article-title":"Global HIV antiretroviral drug resistance: a perspective and report of a national Institute of allergy and infectious diseases consultation","volume":"216","author":"Godfrey","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.bbrc.2021.05.094_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/ml100289m","article-title":"Design of substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient syntheses of bis-THF and substituted bis-THF ligands","volume":"2","author":"Ghosh","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2021.05.094_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28020","article-title":"A\u00a0novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency","volume":"6","author":"Aoki","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bbrc.2021.05.094_bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cmdc.201700824","article-title":"Design of highly potent, dual-acting and central-nervous-system-penetrating HIV-1 protease inhibitors with excellent potency against multidrug-resistant HIV-1 variants","volume":"13","author":"Ghosh","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2021.05.094_bib20","first-page":"342","article-title":"Sparse representation for prediction of HIV-1 protease drug resistance","volume":"2013","author":"Yu","year":"2013","journal-title":"Proc. SIAM Int. Conf. Data Min."},{"key":"10.1016\/j.bbrc.2021.05.094_bib21","first-page":"13","article-title":"Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structure","volume":"5","author":"Yu","year":"2014","journal-title":"BMC. Genom. Supplement"},{"key":"10.1016\/j.bbrc.2021.05.094_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2105-16-S17-S1","article-title":"Identifying representative drug resistant mutants of HIV","volume":"16","author":"Yu","year":"2015","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.bbrc.2021.05.094_bib23","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.biochem.6b00012","article-title":"Binding of clinical inhibitors to a model precursor of a rationally selected multidrug resistant HIV-1 protease is significantly weaker than to the released mature enzyme","volume":"55","author":"Park","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2021.05.094_bib24","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1021\/acsomega.9b00683","article-title":"Highly drug-resistant HIV-1 protease mutant PRS17 shows enhanced binding to substrate analogues","volume":"4","author":"Agniswamy","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbrc.2021.05.094_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168616","article-title":"Structural studies of a rationally selected multi-drug resistant HIV-1 protease reveal synergistic effect of distal mutations on flap dynamics","volume":"11","author":"Agniswamy","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2021.05.094_bib26","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/bi2018317","article-title":"HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements","volume":"51","author":"Agniswamy","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2021.05.094_bib27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.str.2005.11.005","article-title":"Wide-open\" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target","volume":"13","author":"Martin","year":"2005","journal-title":"Structure"},{"key":"10.1016\/j.bbrc.2021.05.094_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbrc.2021.05.094_bib29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1107\/S0907444903028956","article-title":"Likelihood-enhanced fast rotation functions","volume":"60","author":"Storoni","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2021.05.094_bib30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1107\/S0907444905001617","article-title":"Likelihood-enhanced fast translation functions","volume":"61","author":"McCoy","year":"2005","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2021.05.094_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2021.05.094_bib32","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2021.05.094_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/nar\/27.1.348","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"27","author":"Shafer","year":"1999","journal-title":"Nucleic Acids Res."},{"issue":"2019","key":"10.1016\/j.bbrc.2021.05.094_bib34","first-page":"111","article-title":"Update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir. Med."},{"key":"10.1016\/j.bbrc.2021.05.094_bib35","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/AAC.00574-10","article-title":"HIV-1 protease mutations and protease inhibitor cross-resistance","volume":"54","author":"Rhee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2021.05.094_bib36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/AAC.46.4.1086-1092.2002","article-title":"Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy","volume":"46","author":"Kantor","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2021.05.094_bib37","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1021\/bi051886s","article-title":"Analysis of HIV-1 CRF_01 A\/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir","volume":"45","author":"Clemente","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2021.05.094_bib38","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1128\/AAC.00592-09","article-title":"Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations","volume":"53","author":"Shahriar","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2021.05.094_bib39","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1111\/j.1742-4658.2005.04923.x","article-title":"Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs","volume":"272","author":"Tie","year":"2005","journal-title":"FEBS J."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21008858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21008858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:40:15Z","timestamp":1762094415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21008858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":39,"alternative-id":["S0006291X21008858"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.094","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}